Lastly, mechanisms facilitated by cannabinoid binding to TRPV1 and possibly other vanilloid receptors are associated with motor responses to levodopa [193] and also suggest TRPV1 as a potential therapeutic target for PD which is devoid of dyskinesia [194]. The gene discussed is TRPV1; the disease is Dyskinesia.